ERBB2 and breast carcinoma: Although these tumors mostly consisted of HER2-enriched tumors and mimicked HER2-positive breast cancers, no significant overexpression, gain/amplification or elevated mutation rate was discovered for ERBB2 (Fig. 4e and Supplementary Fig. S8a, b).